Cancer Cells Hijack a Protein Switch to Survive Oxidative Death

Cancer cells routinely experience abnormally high levels of reactive oxygen species (ROS) generated by their intense metabolic activity. To survive, they amplify antioxidant defenses—most critically, production of the tripeptide glutathione (GSH). GSH cofactors the lipid-peroxide-reducing enzyme GPX4, and its depletion triggers ferroptosis, an iron-dependent, lipid-peroxidation-driven cell death increasingly targeted in cancer therapy. Understanding precisely how GSH synthesis is rapidly upregulated under oxidative stress therefore has direct therapeutic relevance.

This study focused on GCLC, the catalytic subunit of glutamate-cysteine ligase and the rate-limiting enzyme in GSH biosynthesis. The authors investigated whether succinylation—transfer of a succinyl group to lysine residues—regulates GCLC activity. Using in vitro succinylation assays with purified protein and succinyl-CoA, in-cell co-immunoprecipitation, and site-directed mutagenesis of all 40 lysine residues, they identified K38, K126, and K326 as the three principal succinylation sites. Mutation of all three to glutamate (3KE, mimicking permanent succinylation) nearly abolished GCLC enzymatic activity and GSH synthesis, while arginine substitutions (3KR, mimicking desuccinylation) had little effect on basal activity but prevented succinylation-dependent inhibition.

Critically, treatment of multiple cancer cell lines with the oxidative stressors TBH or H₂O₂ triggered a dose- and time-dependent decrease in GCLC succinylation that paralleled an increase in cellular GSH. This desuccinylation response was also confirmed in vivo: mice injected intraperitoneally with TBH showed reduced hepatic GCLC succinylation and elevated liver GSH at 16 hours post-treatment. Reconstitution experiments in GCLC-knockdown cells demonstrated that only wild-type GCLC, not the 3KE mutant, restored GSH synthesis under TBH challenge, directly linking desuccinylation to oxidative stress-driven GSH upregulation.

The desuccinylase responsible was identified as SIRT2, an NAD⁺-dependent deacylase. SIRT2 directly bound GCLC, and this interaction was substantially enhanced upon ROS treatment. Depletion of SIRT2 elevated GCLC succinylation, reduced total GSH, and sensitized cancer cells to the ferroptosis inducer RSL3, effects largely rescued by re-introduction of wild-type but not 3KE GCLC. Conversely, the histone acetyltransferase P300 was identified as the succinyltransferase that adds the succinyl tag to GCLC; P300–GCLC association was markedly reduced after ROS treatment, explaining how oxidative stress tips the balance toward desuccinylation.

Together, these findings delineate a ROS-sensitive molecular rheostat: under oxidative stress, P300 dissociates from GCLC while SIRT2 binding is enhanced, resulting in net desuccinylation and activation of GCLC, increased GSH, and ferroptosis resistance. This SIRT2–GCLC succinylation axis constitutes a previously unrecognized adaptive mechanism exploited by cancer cells and may represent a tractable target for pro-ferroptotic cancer therapies.